Login to Your Account

Keryx Reports Positive Phase II Results In Diabetic Neuropathy

By Randall Osborne

Monday, May 9, 2005
With plans under way for pivotal trials with its oral heparinoid for diabetic neuropathy, KRX-101, Keryx Pharmaceuticals Inc. reported positive interim Phase II results - and watched Wall Street take value back from the stock, which had run up starting in late April. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription